Long-term results showed that conjugated equine oestrogens (CEE) alone significantly decreased breast cancer incidence, whilst CEE plus medroxyprogesterone acetate (MPA) use significantly increased breast cancer incidence. Both effects were long-term and persisted over a decade after discontinuing use.
The Women’s Health Initiative is a multi-component study designed to address determinants of major chronic disease in women, including breast cancer . Between 1993 and 1998, postmenopausal women between 50 and 79 years with no prior breast cancer and with mammogram clearance were enrolled in 1 of 2 randomised clinical trials at 40 United States (US) centres. Follow-up continued through September 2016. The randomised, placebo-controlled trial interventions were either CEE 0.625 mg/day plus MPA 2.5 mg/day (n=8,506) versus placebo (n=8,102) for a median of 5.6 years for women with a uterus, or CEE alone (n=5,310) versus placebo (n=5,429) for a median of 7.2 ...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement Next Article
High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients »